Staff View: Cardiorespiratory Progression Over 5 Year and Role of Corticosteroids in Duchenne Muscular Dystrophy A Single-Site Retrospective Longitudinal Study

Cardiorespiratory Progression Over 5 Year and Role of Corticosteroids in Duchenne Muscular Dystrophy A Single-Site Retrospective Longitudinal Study

BACKGROUND: Corticosteroids (CSs) have prolonged survival and respiratory function in boys with Duchenne muscular dystrophy (DMD) when compared with CSs-naive boys. RESEARCH QUESTION: The differential impact of frequently used CSs and their regimens on long-term (> 5 years) cardiorespiratory prog...

Full description

Saved in:

Bibliographic Details
Main Authors:	Trucco, Federica, Domingos, Joana P., Tay, Chee Geap, Ridout, Deborah, Maresh, Kate, Munot, Pinki, Sarkozy, Anna, Robb, Stephanie, Quinlivan, Rosaline, Riley, Mollie, Burch, Michael, Fenton, Matthew, Wallis, Colin, Chan, Elaine, Abel, Francois, Manzur, Adnan Y., Muntoni, Francesco
Format:	Article
Published:	ELSEVIER 2020
Subjects:	RJ Pediatrics
Online Access:	http://eprints.um.edu.my/36387/
Tags:	Add Tag No Tags, Be the first to tag this record!

id	my.um.eprints.36387
record_format	eprints
spelling	my.um.eprints.363872023-12-29T07:10:51Z http://eprints.um.edu.my/36387/ Cardiorespiratory Progression Over 5 Year and Role of Corticosteroids in Duchenne Muscular Dystrophy A Single-Site Retrospective Longitudinal Study Trucco, Federica Domingos, Joana P. Tay, Chee Geap Ridout, Deborah Maresh, Kate Munot, Pinki Sarkozy, Anna Robb, Stephanie Quinlivan, Rosaline Riley, Mollie Burch, Michael Fenton, Matthew Wallis, Colin Chan, Elaine Abel, Francois Manzur, Adnan Y. Muntoni, Francesco RJ Pediatrics BACKGROUND: Corticosteroids (CSs) have prolonged survival and respiratory function in boys with Duchenne muscular dystrophy (DMD) when compared with CSs-naive boys. RESEARCH QUESTION: The differential impact of frequently used CSs and their regimens on long-term (> 5 years) cardiorespiratory progression in children with DMD is unknown. STUDY DESIGN AND METHODS: This was a retrospective longitudinal study including children with DMD followed at Dubowitz Neuromuscular Centre, Great Ormond Street Hospital London, England, from May 2000 to June 2017. Patients enrolled in any interventional clinical trials were excluded. We collected patients' anthropometrics and respiratory (FVC, FVC % predicted and absolute FVC, and noninvasive ventilation requirement NIV]) and cardiac (left ventricular shortening function LVFS%]) function. CSs-naive patients had never received CSs. Patients who were treated with CSs took either deflazacort or prednisolone, daily or intermittently (10 days on/10 days off) for > 1 month. Average longitudinal models were fitted for yearly respiratory (FVC % predicted) and cardiac (LVFS%) progression. A time-to-event analysis to FVC % predicted < 50%, NIV start, and cardiomyopathy (LVFS% < 28%) was performed in CS-treated (daily and intermittent) vs CS-naive patients. RESULTS: There were 270 patients, with a mean age at baseline of 6.2 +/- 2.3 years. The median follow-up time was 5.6 +/- 3.5 years. At baseline, 263 patients were ambulant. Sixty-six patients were treated with CSs daily, 182 patients underwent CSs intermittent > 60% treatment, and 22 were CS-naive patients. Yearly FVC % predicted declined similarly from 9 years (5.9% and 6.9% per year, respectively; P = .27) in the CSs-daily and CSs-intermittent groups. The CSs-daily group declined from a higher FVC % predicted than the CSs-intermittent group (P < .05), and both reached FVC % predicted < 50% and NIV requirement at a similar age, > 2 years later than the CS-naive group. LVFS% declined by 0.53% per year in the CSs-treated group irrespective of the CSs regimen, significantly slower (P < .01) than the CSs-naive group progressing by 1.17% per year. The age at cardiomyopathy was 16.6 years in the CSs-treated group (P < .05) irrespective of regimen and 13.9 years in the CSs-naive group. INTERPRETATION: CSs irrespective of the regimen significantly improved respiratory function and delayed NIV requirement and cardiomyopathy. ELSEVIER 2020-10 Article PeerReviewed Trucco, Federica and Domingos, Joana P. and Tay, Chee Geap and Ridout, Deborah and Maresh, Kate and Munot, Pinki and Sarkozy, Anna and Robb, Stephanie and Quinlivan, Rosaline and Riley, Mollie and Burch, Michael and Fenton, Matthew and Wallis, Colin and Chan, Elaine and Abel, Francois and Manzur, Adnan Y. and Muntoni, Francesco (2020) Cardiorespiratory Progression Over 5 Year and Role of Corticosteroids in Duchenne Muscular Dystrophy A Single-Site Retrospective Longitudinal Study. CHEST, 158 (4). pp. 1606-1616. ISSN 00123692, DOI https://doi.org/10.1016/j.chest.2020.04.043 <https://doi.org/10.1016/j.chest.2020.04.043>. 10.1016/j.chest.2020.04.043
institution	Universiti Malaya
building	UM Library
collection	Institutional Repository
continent	Asia
country	Malaysia
content_provider	Universiti Malaya
content_source	UM Research Repository
url_provider	http://eprints.um.edu.my/
topic	RJ Pediatrics
spellingShingle	RJ Pediatrics Trucco, Federica Domingos, Joana P. Tay, Chee Geap Ridout, Deborah Maresh, Kate Munot, Pinki Sarkozy, Anna Robb, Stephanie Quinlivan, Rosaline Riley, Mollie Burch, Michael Fenton, Matthew Wallis, Colin Chan, Elaine Abel, Francois Manzur, Adnan Y. Muntoni, Francesco Cardiorespiratory Progression Over 5 Year and Role of Corticosteroids in Duchenne Muscular Dystrophy A Single-Site Retrospective Longitudinal Study
description	BACKGROUND: Corticosteroids (CSs) have prolonged survival and respiratory function in boys with Duchenne muscular dystrophy (DMD) when compared with CSs-naive boys. RESEARCH QUESTION: The differential impact of frequently used CSs and their regimens on long-term (> 5 years) cardiorespiratory progression in children with DMD is unknown. STUDY DESIGN AND METHODS: This was a retrospective longitudinal study including children with DMD followed at Dubowitz Neuromuscular Centre, Great Ormond Street Hospital London, England, from May 2000 to June 2017. Patients enrolled in any interventional clinical trials were excluded. We collected patients' anthropometrics and respiratory (FVC, FVC % predicted and absolute FVC, and noninvasive ventilation requirement NIV]) and cardiac (left ventricular shortening function LVFS%]) function. CSs-naive patients had never received CSs. Patients who were treated with CSs took either deflazacort or prednisolone, daily or intermittently (10 days on/10 days off) for > 1 month. Average longitudinal models were fitted for yearly respiratory (FVC % predicted) and cardiac (LVFS%) progression. A time-to-event analysis to FVC % predicted < 50%, NIV start, and cardiomyopathy (LVFS% < 28%) was performed in CS-treated (daily and intermittent) vs CS-naive patients. RESULTS: There were 270 patients, with a mean age at baseline of 6.2 +/- 2.3 years. The median follow-up time was 5.6 +/- 3.5 years. At baseline, 263 patients were ambulant. Sixty-six patients were treated with CSs daily, 182 patients underwent CSs intermittent > 60% treatment, and 22 were CS-naive patients. Yearly FVC % predicted declined similarly from 9 years (5.9% and 6.9% per year, respectively; P = .27) in the CSs-daily and CSs-intermittent groups. The CSs-daily group declined from a higher FVC % predicted than the CSs-intermittent group (P < .05), and both reached FVC % predicted < 50% and NIV requirement at a similar age, > 2 years later than the CS-naive group. LVFS% declined by 0.53% per year in the CSs-treated group irrespective of the CSs regimen, significantly slower (P < .01) than the CSs-naive group progressing by 1.17% per year. The age at cardiomyopathy was 16.6 years in the CSs-treated group (P < .05) irrespective of regimen and 13.9 years in the CSs-naive group. INTERPRETATION: CSs irrespective of the regimen significantly improved respiratory function and delayed NIV requirement and cardiomyopathy.
format	Article
author	Trucco, Federica Domingos, Joana P. Tay, Chee Geap Ridout, Deborah Maresh, Kate Munot, Pinki Sarkozy, Anna Robb, Stephanie Quinlivan, Rosaline Riley, Mollie Burch, Michael Fenton, Matthew Wallis, Colin Chan, Elaine Abel, Francois Manzur, Adnan Y. Muntoni, Francesco
author_facet	Trucco, Federica Domingos, Joana P. Tay, Chee Geap Ridout, Deborah Maresh, Kate Munot, Pinki Sarkozy, Anna Robb, Stephanie Quinlivan, Rosaline Riley, Mollie Burch, Michael Fenton, Matthew Wallis, Colin Chan, Elaine Abel, Francois Manzur, Adnan Y. Muntoni, Francesco
author_sort	Trucco, Federica
title	Cardiorespiratory Progression Over 5 Year and Role of Corticosteroids in Duchenne Muscular Dystrophy A Single-Site Retrospective Longitudinal Study
title_short	Cardiorespiratory Progression Over 5 Year and Role of Corticosteroids in Duchenne Muscular Dystrophy A Single-Site Retrospective Longitudinal Study
title_full	Cardiorespiratory Progression Over 5 Year and Role of Corticosteroids in Duchenne Muscular Dystrophy A Single-Site Retrospective Longitudinal Study
title_fullStr	Cardiorespiratory Progression Over 5 Year and Role of Corticosteroids in Duchenne Muscular Dystrophy A Single-Site Retrospective Longitudinal Study
title_full_unstemmed	Cardiorespiratory Progression Over 5 Year and Role of Corticosteroids in Duchenne Muscular Dystrophy A Single-Site Retrospective Longitudinal Study
title_sort	cardiorespiratory progression over 5 year and role of corticosteroids in duchenne muscular dystrophy a single-site retrospective longitudinal study
publisher	ELSEVIER
publishDate	2020
url	http://eprints.um.edu.my/36387/
_version_	1787133817600868352
score	13.211869

Cardiorespiratory Progression Over 5 Year and Role of Corticosteroids in Duchenne Muscular Dystrophy A Single-Site Retrospective Longitudinal Study

Similar Items